Terminated
Proprietary Information - Exploratory (Non-confirmatory) Trial
Led by Merck Sharp & Dohme LLC · Updated on 2015-11-23
12
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain). This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
CONDITIONS
Brief Title
A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months
- Able to complete study questionnaires, patient diary, and comply with daily study medication
- Patient is not satisfied with current treatment for pain control
You will not qualify if you...
- Pregnant or nursing female
- History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here